DMRA vs GERN
DMRA: Damora Therapeutics is a biotechnology company developing a pipeline of precision antibody therapies specifically targeting mutCALR-driven myeloproliferative neoplasms. GERN: First-in-class telomerase inhibitor company with FDA-approved RYTELO for myelodysplastic syndromes, now expanding into myelofibrosis with Phase 3 clinical data pending.
Side-by-side fundamentals
| Metric | DMRA | GERN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $29.99 | $1.41 | |
| Market cap as of 2026-07-23 | $1.8B | $917M | |
| PEG as of 2026-07-23 | -0.00 | n/a | |
| Net margin as of 2026-07-23 | n/a | -34.3% | |
| Gross margin as of 2026-07-23 | n/a | +97.3% | |
| Operating margin as of 2026-07-23 | n/a | -26.4% | |
| ROE as of 2026-07-23 | -123.1% | -28.0% | GERN higher |
| ROA as of 2026-07-23 | -115.7% | -12.1% | GERN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.09 | DMRA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +68.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | -4.33 | 0.58 | |
| 1-year return as of 2026-07-22 close | +29.3% | +17.1% | DMRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.